Hájek, RomanMinařík, JiříStraub, JanPour, LuděkJungova, AlexandraBerdeja, Jesus G.Boccadoro, MarioBrozova, LucieSpencer, Andrewvan Rhee, FritsVela-Ojeda, JorgeThompson, Michael A.Abonour, RafatChari, AjaiCook, GordonCostello, Caitlin L.Davies, Faith E.Hungria, Vania T. M.Lee, Hans C.Leleu, XavierPuig, NoemiRifkin, Robert M.Terpos, EvangelosUsmani, Saad Z.Weisel, Katja C.Zonder, Jeffrey A.Bařinová, MagdaKuhn, Matyᚊilar, JiříČápková, LenkaGalvez, KennyLu, JinElliott, JenniferStull, Dawn MarieRen, KailiMaisnar, Vladimír2024-07-232024-07-232021Hájek R, Minařík J, Straub J, et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021;17(19):2499-2512. doi:10.2217/fon-2020-1225https://hdl.handle.net/1805/42379Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalEffectivenessIxazomibMultiple myelomaProteasome inhibitorRelapsed/refractoryRoutine clinical practiceArticle